Evidence map›Paper›PMID 28692054›Full record

ArticleOncogene2017

Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing.

H Huskova, M Ardin, A Weninger, K Vargova, S Barrin, S Villar, M Olivier, T Stopka, Z Herceg, M Hollstein and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

H HuskovaMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
M ArdinMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
A WeningerDeutsches Krebsforschungszentrum, Heidelberg, Germany.
K VargovaPathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
S BarrinDynamics of T cell Interactions Team, Institut Cochin, Inserm U1016, Paris, France.
S VillarMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
M OlivierMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
T StopkaBiocev, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Z HercegEpigenetics Group, International Agency for Research on Cancer, Lyon, France.
M HollsteinMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
J ZavadilMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-0640-5562
M KorenjakMolecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France.
Centre international de recherche sur le cancer · FRCharles University · CZGerman Cancer Research Center · DEInserm · FRUniversity of Leeds · GB

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
NCI NIH HHS P30 CA016087World Health Organization 001
6 · The paper itself

Abstract

The information on candidate cancer driver alterations available from public databases is often descriptive and of limited mechanistic insight, which poses difficulties for reliable distinction between true driver and passenger events. To address this challenge, we performed in-depth analysis of whole-exome sequencing data from cell lines generated by a barrier bypass-clonal expansion (BBCE) protocol. The employed strategy is based on carcinogen-driven immortalization of primary mouse embryonic fibroblasts and recapitulates early steps of cell transformation. Among the mutated genes were almost 200 COSMIC Cancer Gene Census genes, many of which were recurrently affected in the set of 25 immortalized cell lines. The alterations affected pathways regulating DNA damage response and repair, transcription and chromatin structure, cell cycle and cell death, as well as developmental pathways. The functional impact of the mutations was strongly supported by the manifestation of several known cancer hotspot mutations among the identified alterations. We identified a new set of genes encoding subunits of the BAF chromatin remodeling complex that exhibited Ras-mediated dependence on PRC2 histone methyltransferase activity, a finding that is similar to what has been observed for other BAF subunits in cancer cells. Among the affected BAF complex subunits, we determined Smarcd2 and Smarcc1 as putative driver candidates not yet fully identified by large-scale cancer genome sequencing projects. In addition, Ep400 displayed characteristics of a driver gene in that it showed a mutually exclusive mutation pattern when compared with mutations in the Trrap subunit of the TIP60 complex, both in the cell line panel and in a human tumor data set. We propose that the information generated by deep sequencing of the BBCE cell lines coupled with phenotypic analysis of the mutant cells can yield mechanistic insights into driver events relevant to human cancer development.

Indexed as

High-Throughput Nucleotide SequencingAnimalsCell Transformation, NeoplasticExomeFibroblastsHumansMiceMutationNeoplasm ProteinsNeoplasmsPrimary Cell CultureNeoplasm Proteins

Identifiers

PMID28692054
PMCPMC5666318
OpenAlexW2735575797

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.